What is Exelixis's deferred revenue, net of current portion?

Exelixis (EXEL) reported deferred revenue, net of current portion of $5.16M in Q1 2026.

How has Exelixis's deferred revenue, net of current portion changed year-over-year?

Exelixis's deferred revenue, net of current portion increased by 67.3% year-over-year, from $3.09M to $5.16M.

What is the long-term trend for Exelixis's deferred revenue, net of current portion?

Over 5 years (2020 to 2025), Exelixis's deferred revenue, net of current portion has grown at a 10.2% compound annual growth rate (CAGR), from $3.76M to $6.11M.

Exelixis EXEL Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Regeneron PharmaceuticalsREGN

$225.1M+6.3%

Ionis PharmaceuticalsIONS

——

BridgeBio PharmaBBIO

——

ModernaMRNA

——

Other financials

Income statement

See full

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

See full

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

See full

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation

See full

Market cap$13.05B+10.1%

Enterprise value$12.99B+9.5%

P/E15.7×-2.8×

P/S5.5×+0.3×

Profitability

See full

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

See full

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exelixis's deferred revenue, net of current portion?: Exelixis (EXEL) reported deferred revenue, net of current portion of $5.16M in Q1 2026.
How has Exelixis's deferred revenue, net of current portion changed year-over-year?: Exelixis's deferred revenue, net of current portion increased by 67.3% year-over-year, from $3.09M to $5.16M.
What is the long-term trend for Exelixis's deferred revenue, net of current portion?: Over 5 years (2020 to 2025), Exelixis's deferred revenue, net of current portion has grown at a 10.2% compound annual growth rate (CAGR), from $3.76M to $6.11M.